e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Translational research to bridge the need within clinical decision making
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chemokines CXCL12 and CCL21 may contribute to the development of lung cancer in COPD patients
B. Kuznar-Kaminska, J. Mikula-Pietrasik, K. Ksiazek, H. Batura-Gabryel (Poznan, Poland)
Source:
Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Session:
Translational research to bridge the need within clinical decision making
Session type:
Thematic Poster Session
Number:
553
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Kuznar-Kaminska, J. Mikula-Pietrasik, K. Ksiazek, H. Batura-Gabryel (Poznan, Poland). Chemokines CXCL12 and CCL21 may contribute to the development of lung cancer in COPD patients. Eur Respir J 2013; 42: Suppl. 57, 553
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Increased expression of a proliferation-inducing ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: A possible link between COPD and lung cancer?
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
The impact of chronic obstructive pulmonary disease on survival of the patients with small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Osteopontin levels in sputum supernatant and serum of patients with lung cancer: Does coexistent COPD make the difference?
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013
Increased sirtuin expression in patient with lung squamous cell carcinoma co-morbid with COPD
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Prognostic affect of the chronic obstructive pulmonary disease on the local-advanced stage non-small cell lung cancer
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Serum osteopontin as a prognostic marker in patients with lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
COPD and lung cancer: Prevalence, infradiagnosis, phenotypes and multidimensional characterization
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
The impact of pulmonary rehabilitation on preoperative inflammatory markers in lung cancer patients
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Prevalence of COPD and emphysema at the time of diagnosis of primary lung cancer
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
DNA methylation profiling of non-small cell lung cancer reveals an immune signature in COPD patients
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Lymphocyte profile in the BALF from affected lung in comparison to healthy lung and systemic inflammation in lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Epigenetic alterations in the circulating DNA from blood of patients with COPD and lung cancer
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
IL-17C promotes tumor-associated inflammation and lung tumor growth
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Stereotactic body radiation does not impair respiratory health in patients with stage I non-small cell lung cancer
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Weight loss cutoff level as a key variable related to death risk among advanced lung cancer patients
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Lung diseases infection and risk of lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept